Multidrug Resistance in Aggressive Lymphoproliferative Disorders of T and Natural-Killer Origin

References

• Arceci R.J. Clinical significiance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215–2222
   PubMed Web of Science ®Google Scholar
• McKenna S.L., Padua R.A. Multidrug resistance in leukemia. Br. J. Haematol. 1997; 96: 659–674
   PubMed Web of Science ®Google Scholar
• Roninson I.B., Chin J.E., Choi K.G., Gros P., Housman D.E., Fojo A., Shen V., Goettesman M.M., Pastan I. Isolation of human MDR DN A sequences amplified in mutlidrug-resistant KB carcinoma-cells. Proc. Natl. Acad. Sci. 1986; 83: 4538–4542
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170- to 180-κDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Scheper R.J., Broxterman H.J., Scheffer G.L., Kaajik P., Dalton W.S., van Heijningen T.H.M., van Kalken C.K., Slovack M.L., de Vries E.G.E., van der Valk P., Meijer C. J. L. M., Pinedo H.M. Overexpression of a Mr 110.000 vesicular protein in Non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Scheffer G.L., Winjgaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C. J. L. M., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nature Med. 1995; 1: 578–582
   PubMed Web of Science ®Google Scholar
• Chaudary P.M., Roninson J.B. Expression and activity of P-Glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Davey M.W., Hargrave R.M., Davey R.A. Comparison of drug accumulation in P-glycoprotein expressing and MRP-expressing human leukaemia cells. Leuk. Res. 1996; 20: 657–664
   PubMed Web of Science ®Google Scholar
• Webb M., Raphael C.L., Asbahr H., Erber W.N., Meyer B.F. The detection of rhodamine 123 efflux at low levels of drug resistance. Br. J. Haematol. 1996; 93: 650–655
   PubMed Web of Science ®Google Scholar
• Lennert K., Feller A.C. Histopathologic der Non-Hodgkin Lymphome. Springer-Verlag, Berlin and Heidelberg 1990, (Nach der aktualiesierten Kiel Klassification)
   Google Scholar
• Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K.C., Grogan T.M., Isaacson P., Knowles D.M., Mason D., Müller-Hermelink H.K., Pileri S.A., Piris M.A., Ralfkiaer E., Warnke R.A. A revised European-American Classification of lymphoid neoplasms: A proposal from the International lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Neyfackh A. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp. Cell. Res. 1988; 174: 168–176
   PubMed Web of Science ®Google Scholar
• Coon J.S., Wang Y., Bines S.D., Markham P.N., Chong A.S.F., Gebel H.M. Multidrug resistance activity in human lymphocytes. Hum. Immunol. 1991; 32: 134–140
   PubMed Web of Science ®Google Scholar
• Lamy T., Grulois I., Drénou B., Fardel O., Le Prisé P.Y., Semana G., Genetet N., Fauchet R. High PgP activity measured by rhodamine 123 efflux asay in CD3, CD8, CD56 human lymphocytes and in CD3+, CD57+ large granular lymphocyte proliferative disorders. (GLPD). Br. J. Hematol. 1994; 87: 112
   Google Scholar
• Yuen A., Sikic B.I. Multidrug resistance in lymphomas. J. Clin. Oncol. 1994; 12: 2453–2459
   PubMed Web of Science ®Google Scholar
• Lamy T., Drenou B., Grulois I., Fardel O., Jacquelinet C., Goasguen J., Dauriac C., Amiot L., Bernard M., Fauchet R., Le Prise P.Y. Multidrug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995; 9: 1549–1555
   PubMed Web of Science ®Google Scholar
• Paietta E., Andersen J., Racevskis J., Ashigbi M., Cassileth P., Wiernik P.H. Modulation of multidrug resistance in de novo., acute myeloid leukemia: variable efficacy of reverting agents in vitro. Blood reviews 1995; 9: 47–52
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D. A. A. G., Granick H.R., Sultan S. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative group. Ann. Intern. Med. 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Bene M.C., Castold G., Knapp W., Ludwig W.D., Matutes E., Orfao A., Van't Veer M.B. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783–1786
   PubMed Web of Science ®Google Scholar
• Loughran T.P. Clonal disease of large granular lymphocytes. Blood 1993; 82: 1–14
   PubMed Web of Science ®Google Scholar
• Semenzato G., Zambello R., Starkebaum G., Oshimi K., Loughran T.P. The lymphoproliferation disease of granular lymphocytes: Updated criteria for diagnosis. Blood, 89: 256–260
   PubMed Web of Science ®Google Scholar
• Drénou B., Lamy T., Amiot L., Fardel O., Caulet-Maugendre S., Sasportes M., Diebold J., Le Prisé P.Y., Fauchet R. CD3-CD56+ Non Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997; 89: 2966–2974
   PubMed Web of Science ®Google Scholar
• Drénou B., Fardel O., Amiot L., Fauchet R. Detection of P-glycoprotein activity in normal and leukemic CD34 positive cells. Leukemia Res. 1993; 17: 1031–1035
   PubMed Web of Science ®Google Scholar
• Sambrook J., Fritsch E.F., Maniatis T. Purification of nucleid acids. Molecular cloning 2nd ed., J. Sambrook, E.F. Fritsch, T. Maniatis. Cold Spring Harbor Laboratory Press. 1989; vol. 3: E.3
   Google Scholar
• Mac Intyre E., D'Auriol L., Amesland F., Loiseau P., Chen, Boumsell L., Galibert F., Sigaux F. Analysis of junctionnal diversity in the preferential V-J rearrangement for fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing. Blood 1989; 74: 2053–2061
   PubMed Web of Science ®Google Scholar
• Jaffe E.S., Chan J.K.C., Su I.J., Frizzera G., Mori S., Feller A.C., Ho F.C.S. Report of the workshop on nasal and related extranodal angiocentric T/NK-cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 1996; 20: 103–111
   PubMed Web of Science ®Google Scholar
• Emile J.F., Boulland M.L., Haioun C., Kanavaros P., Petrella T., Delfau-Larue M.H., Bensussan A., Farcet J.P., Gaulard P. CD5—CD56+ “TCR silent peripheral T-cell lymphomas” are natural killer cell lymphomas. Blood 1996; 87: 1466–1473
   PubMed Web of Science ®Google Scholar
• Tefferi A., Li C.Y., Witzig T.E., Dhodapkar M.V., Okuno S.H., Phyliky R.L. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 1994; 84: 2721–2725
   PubMed Web of Science ®Google Scholar
• Sivakumaran M., Richards S.J., Scott C.S. Clinical and laboratory characteristics of chronic natural killer cell lymphocytosis. Blood 1996; 87: 1659–1560
   PubMed Web of Science ®Google Scholar
• Imamura N., Kusunoki Y., Kawa-Ha K., Yumura K., Hatra J., Oda K., Abe K., Dohy H., Inada T., Kajihara H., Kuramoto A. Aggressive natural killer cell leukemia/lymphoma: report of four cases and review of the literature. Br. Haematol. 1990; 75: 49–59
   PubMed Web of Science ®Google Scholar
• Wong K.F., Chan J.K.C., Ng C.S., Lee K.C., Tsang W.Y.W., Cheung M.M.C. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum. Pathol. 1992; 23: 798–804
   PubMed Web of Science ®Google Scholar
• Kanavaros P., Lescs M.C., Brière J., Divine M., Galateau F., Joab I., Bosq J., Farcet J.P., Reyes F., Gaulard P. Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688–2695
   PubMed Web of Science ®Google Scholar
• Kern W.F., Spier C.M., Hanneman E.H., Miller T.P., Matzner M., Grogan T.M. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992; 79: 2432–2437
   PubMed Web of Science ®Google Scholar
• Kwong Y.L., Chan A.C.L., Liang R., Chiang A.K.S., Chim C.S., Chan T.K., Todd D., Ho F.C.S. CD56+ NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol. 1997; 97: 821–829
   PubMed Web of Science ®Google Scholar
• Chan J.K.C., Sin V.C., Ng C.S., Tsang W.Y.W., Chan C. Ft, Cheung M.M.C., Lau W.H. Non nasal lymphoma expressing the natural killer cell marker CD56: a clinicopathological study of 49 cases of an uncommon agres-sive neoplasm. Blood 1997; 89: 4501–4513
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Iwasaki T., Watanabe N., Oshimi K., Naito M., Tsuruo T., Kobayashi Y. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood 1993; 81: 1342–2356
   PubMed Web of Science ®Google Scholar
• Yamaguchi M., Kita K., Miwa H., Nishii K., Oka K., Ohno T., Shirakawa S., Fukumoto M. Frequent expression of P-glycoprotein/MDR1 by Nasal T-Cell lymphoma cells. Cancer 1995; 76: 2351–2356
   PubMed Web of Science ®Google Scholar
• Weisburg J.H., Curcio M., Caron P.C., Raghu G., Mechetner E.B., Roepe P.D., Scheinberg D.A. The multidrug resistance phenotype confers immunological resistance. J Exp Med 1996; 183: 2699–2704
   PubMed Web of Science ®Google Scholar
• Raghu G., Park S.W., Roninson I.B., Metcheter E.B. Monoclonal antibodies against P-glycoprotein and MDR1 gene product inhibit interleukin 2 release from PHA-activated lymphocytes. Exp. Hematol. 1996; 24: 1258–1264
   PubMed Web of Science ®Google Scholar
• Chong A.S.F., Markham P.N., Gebel H.M., Bines S.D., Coon J.S. Diverse multidrug-resistance modification agents inhibit cytolytic activity of natural killer cells. Cancer. Immuno. Immunother. 1993; 36: 133–136
   PubMed Web of Science ®Google Scholar
• Matutes E., Brito-Babapulle V., Swansbury J., Ellis J., Morilla R., Dearden C., Sempere A., Catovsky D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78: 3269–3274
   PubMed Web of Science ®Google Scholar
• Burger H., Nooter K., Sonneveld P., Van Wingerden K.E., Zaman G.J.R., Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocyte leukaemia. Br. J. Haematol. 1994; 88: 348–356
   PubMed Web of Science ®Google Scholar
• Diamandidou E., Cohen P.R., Kurzrock R. Mycosis fungoide and Sezary syndrome. Blood 1996; 88: 2385–2409
   PubMed Web of Science ®Google Scholar
• Burger H., Nooter K., Zaman G.J.R., Sonneveld P., van Wingerden K.E., Oostrum R.G., Stoter G. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia. 1994; 8: 990–997
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Ermacora A., Raspadori D., Michelutti A., Grimaz S., Fanin R., Russo D., Lauria F., Masolini P., Baccarani M. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukemic blast cells. Br. J. Haematol. 1997; 96: 356–365
   PubMed Web of Science ®Google Scholar